Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27440639 | 0.78 | ADRA2A (0.33) | NOS3 | |
| SCHEMBL17307151 | 0.70 | CA2 (0.38) | — | |
| SCHEMBL17460765 | 0.69 | — | — | |
| SCHEMBL3680298 | 0.68 | HTR6 (0.37) | — | |
| SCHEMBL27973813 | 0.68 | SRD5A1 (0.52) | SRD5A1NOS3NOS2 | |
| SCHEMBL27963635 | 0.67 | HTR6 (0.36) | — | |
| SCHEMBL27440641 | 0.63 | ACHE (0.39) | SRD5A1NOS3KCNH2TMEM97SIGMAR1 | |
| SCHEMBL27441649 | 0.63 | CYP3A4 (0.36) | SRD5A1NOS3NOS2KCNH2TMEM97 | |
| SCHEMBL79047 | 0.61 | ACHE (0.39) | KCNH2 | |
| SCHEMBL1623884 | 0.60 | TTR (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | SRD5A1 4651/4885NOS3 3501/4885NOS2 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.